EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery

Capucine Barjot, Thomas Gaillard, Romain-David Seban, Lauren Darrigues, Delphine Loirat, Luc Cabel, Jean-Guillaume Feron, Virginie Fourchotte, Benoit Couturaud, Claire Bonneau, Kim Cao, Fabien Reyal und 1 weitere

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.110511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Capucine Barjot und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast, Gynecology and Reconstructive Surgery, Institut Curie, 75005, Paris, France; Institut of Women Cancer, Institut Curie, Paris, F…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Postoperative Complications, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant pembrolizumab combined with chemotherapy is now standard treatment for stage II and III triple-negative breast cancer (TNBC). However, its impact on postoperative complications remains underexplored especially in oncoplastic or reconstructive procedures. METHODS: A retrospective before-and-after study was conducted at a single institution from January 2019 to May 2023. Patients with early-stage TNBC treated with chemotherapy alone (CT group) or chemotherapy plus pembrolizumab (CT + P group) were included. Postoperative complications (including delayed wound healing, abscesses, hematomas, infections, implant exposure, and skin necrosis) were compared using univariate and multivariate logistic regression. RESULTS: Among 254 patients (CT: n = 136; CT + P: n = 118), the overall complication rate was 15.7 %. No significant difference was observed between groups (p = 0.061). Delayed wound healing was more frequent in the CT + P group (10 % vs. 3.8 %, p = 0.031). After adjustment, immunotherapy was not independently associated with higher risk (OR 1.27, p = 0.5). Oncoplastic surgeries were associated with higher complication rates in univariate analysis but not in multivariate analysis (OR 1.74, p = 0.2). Complications were more frequent when surgery occurred 30 days post-treatment (p = 0.029), especially among CT + P patients (interaction p = 0.01). CONCLUSION: Neoadjuvant pembrolizumab does not significantly increase postoperative complications. Surgical timing appears to be a modifiable factor influencing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyPostoperative ComplicationsAntibodies, Monoclonal, HumanizedTriple Negative Breast NeoplasmsMastectomyMammaplastyAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedRetrospective StudiesAgedAdultNeoplasm StagingAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

ImplantNeoadjuvant pembrolizumabOncoplastic surgeryPostoperative complicationsTriple-negative breast cancer

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Breast, Gynecology and Reconstructive Surgery, Institut Curie, 75005, Paris, France; Institut of Women Cancer, Institut Curie, Paris, France. Electronic address: capucine.barjot@gmail.com.
  • Department of Breast, Gynecology and Reconstructive Surgery, Institut Curie, 75005, Paris, France; Institut of Women Cancer, Institut Curie, Paris, France.
  • Department of Nuclear Medicine and endocrine Oncology, Institut Curie, Saint-Cloud, France; Institut of Women Cancer, Institut Curie, Paris, France.
  • Department of Medical Oncology, Institut Curie, 75005, Paris, France; Institut of Women Cancer, Institut Curie, Paris, France.
  • Department of Breast, Gynecology and Reconstructive Surgery, Institut Curie, 92210, Saint-Cloud, France; University of Versailles Saint-Quentin en Yvelines, U1331 STAMPM Team, Saint Cloud, France; Institut of Women Canc…
  • Department of Radiotherapy, Institut Curie, 75005, Paris, France; Institut of Women Cancer, Institut Curie, Paris, France.

Zitieren

APA

Barjot, C., Gaillard, T., Seban, R. D., Darrigues, L., Loirat, D., Cabel, L., Feron, J. G., Fourchotte, V., Couturaud, B., Bonneau, C., Cao, K., Reyal, F., & Laas, E. (2025). Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110511

Vancouver

Barjot C, Gaillard T, Seban RD, Darrigues L, Loirat D, Cabel L, et al. Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110511

BibTeX
@article{Barjot2025,
  author = {Barjot, Capucine and Gaillard, Thomas and Seban, Romain-David and Darrigues, Lauren and Loirat, Delphine and Cabel, Luc and Feron, Jean-Guillaume and Fourchotte, Virginie and Couturaud, Benoit and Bonneau, Claire and Cao, Kim and Reyal, Fabien and Laas, Enora},
  title = {Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.110511}
}
Kostenlos starten →